AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 211 min read$RNXT

RenovoRx Regains Nasdaq Compliance As Shares Maintain $1 Minimum Bid

RenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.

Original reporting
rttnews.com
Published Aug 21, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$RNXTBullishLow
01

Why it matters

Regaining Nasdaq compliance removes a delisting threat, potentially supporting liquidity and investor confidence.

02

Market read

Compliance news is a modest catalyst for RNXT; broader market impact is limited.

03

What to watch

Trial progress and revenue growth could drive longer‑term valuation.

Relevance 5/10Novelty 5/10Timing: pre-market today

Background

RenovoRx is a clinical‑stage biotech developing the RenovoCath device and TIGeR‑PaC trial for pancreatic cancer.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx regained Nasdaq compliance by meeting the $1 minimum bid price for 10 consecutive days.

Expected impact

Potential modest upside as compliance removes delisting risk.

Evidence & confidence

The news removes a regulatory risk factor; no new financial data beyond compliance.

Market effects

Sector

Minimal impact on biotech sector; compliance news is company‑specific.

Regional

No broader regional effect.

Global

Limited to investors in RNXT.

Counterpoint

What could challenge this read

Compliance may be short‑term relief; underlying trial risks remain.

Key entities

  • Company
    RenovoRx

    Biotech firm focused on drug‑delivery devices and cancer trials.

Read at source← All news

Related articles

AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 25
$RNXTMedAI 8/10

RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site

RenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d

stocktitan.net3 min
AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min
AUG 13
$RNXTMedAI 8/10

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.

fool.com6 min
AUG 11
$RNXTMed

RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.

finanznachrichten.de2 min